

UPDATE ADDENDUM—Continued

IND/NDA	Drug	Status	Date	Sponsor
3827	Depo Medrol		Apr. 16, 1969	Do.
5097	Protriptyline HCl and Perphenazine		Jan. 15, 1969	Merck.
5407(L)	SU 177,708		Jan. 13, 1969	Ciba.
5535	U-25030		Mar. 3, 1969	Upjohn.
16-845	Aristosol		Feb. 17, 1969	Lederle.

DR. EARL LONG

IND/NDA	Drug	With Dr. Stough	Date	Sponsor
188	Megestrol Acetate		Feb. 26, 1968	Mead Johnson.
191	Pravast	X	Mar. 27, 1969	Upjohn.
247	Levoxadrol HCl	X	Aug. 28, 1967	Cutter.
453	Bandol			Squibb.
616	Penicillin		Apr. 25, 1968	Bristol.
666	Delestrec Injection	X		Squibb.
1669	Mebutamate		Mar. 22, 1968	Wallace.
1760	Polycillin		Dec. 11, 1967	Bristol.
1766	BL-P #1011		Mar. 23, 1967	Do.
2290	CL #1190C	X	Feb. 20, 1967	Cutter.
2426	SU #14,542	X		Ciba.
2477	Voranil	X		Do.
2498	Hetacillin	X	Mar. 13, 1968	Bristol.
3192	THFES Caps	X		Commercial Solvent.
3196	BA #31531	X		Ciba.
3436	W #1673	X	Jan. 5, 1968	Wallace.
3585	Trobicin Injection	X	Sept. 9, 1968	Upjohn.
3810	Rifampin	X	Dec. 28, 1966	Ciba.
3848	MJ #1992	X	Feb. 25, 1967	Mead Johnson.
4097	U #24, 973 AC 14	X	July 7, 1957	Upjohn.
4177	SC #17914		May 10, 1968	Searle.
4215	WIN #11, 464	X	Sept. 5, 1967	Sterling-Winthrop.
4266	NDR #5204	X	Oct. 3, 1967	National Drug.
4285	Dilabron	X	Oct. 11, 1967	Breon.
4373	Zaroxolyn	X	Jan. 30, 1968	Strassenburg.
4448	Flagyl w/Nystatin	X	Jan. 8, 1968	Searle.
4524	Persol Cream		Oct. 28, 1968	Carter-Wallace.
4557	MK #835		May 1, 1968	Merck.
4643	Megestrol Acetate		Feb. 13, 1969	Mead Johnson.
4814	SCH #12, 69	X	Aug. 2, 1968	Schering.
4821	NDR #5998-A	X	May 14, 1968	National Drug.
4871	U #25,927	X	June 4, 1968	Upjohn.
4884	Anna PM	X	June 10, 1968	Pitman-Moore.
5018	Pentids P #1200	X	July 29, 1968	Squibb.
5046	Riker #760	X	Aug. 7, 1968	Riker.
55036	CL #65,562	X	Aug. 29, 1968	Lederle.
5281	RS 3540	X	Dec. 16, 1968	Syntex.
1407	SU #177,708	X	Jan. 13, 1969	Ciba.
56-826	Bandol		Nov. 13, 1968	Squibb.
50024	Versapen		Aug. 16, 1966	Bristol.
50098	Polycillin IM	X	Nov. 22, 1967	Do.
50102	Dynapen Powder		Feb. 19, 1968	Do.
50103	Dynapen Injection		Feb. 20, 1968	Do.

Senator NELSON. In the last sentence, Dr. Jennings states that although Dr. Lisook's two investigations of Dr. Stough's operations disclosed no violations of our regulations, obviously, we should be concerned that such an operation can exist under current regulations of FDA and the DBS, and so on. "Aside from the welfare of the subjects, the question of validity of the studies may still be raised, especially the possibility of concurrent testing of drugs."

It seems to me that that sentence in itself is a strong indictment of the criticism of the methods being used by Dr. Stough when Dr. Jennings says that we should be concerned that "such an operation can exist under current regulations."